Research Analyst at Goldman Sachs
Nicholas Jennings is an Equity Analyst at Goldman Sachs & Co. LLC specializing in equity research since 2021, following a decade at Stifel, Nicolaus & Co., Inc. and an earlier role at Merrill Lynch. He has covered companies such as BioNTech, as evidenced by his participation in recent earnings calls, with a focus on delivering actionable investment analysis in sectors related to healthcare and consumer services. Jennings holds an MBA from the University of California, Berkeley and an undergraduate degree from Columbia University, and maintains active FINRA broker registrations with multiple securities licenses. With over 14 years of experience in financial analysis and investment banking, he is recognized for his detailed company coverage and professional expertise across major Wall Street firms.
Nic Jennings inquired about expectations for the BNT327 Phase II details in triple-negative breast cancer, which will be presented at SABCS, and whether any new information could provide additional confidence in the Phase III success.
Özlem Türeci, Chief Medical Officer and Co-founder, stated that the company will present efficacy, safety, and dose data for BNT327 in triple-negative breast cancer at SABCS.
Nic Jennings, on behalf of Assad Haider, asked for insights into the BNT327 phase 2 details expected at SABCS, specifically what information could provide additional confidence in the success of the upcoming phase 3 trial in triple-negative breast cancer (TNBC).
Özlem Türeci, Chief Medical Officer and Co-founder, stated that BioNTech plans to present efficacy, safety, and dose data for BNT327 at SABCS.
Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.
Trusted by leading investment firms and analysts